Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

NRX Pharmaceuticals (NRXP) Cash from Operations (2024 - 2025)

NRX Pharmaceuticals (NRXP) has disclosed Cash from Operations for 2 consecutive years, with 3712000.0 as the latest value for Q4 2025.

Quarterly Cash from Operations fell 76.93% to 3712000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 14112000.0 through Dec 2025, down 32.67% year-over-year, with the annual reading at 14112000.0 for FY2025, 32.67% down from the prior year.
Cash from Operations for Q4 2025 was 3712000.0 at NRX Pharmaceuticals, down from 2892000.0 in the prior quarter.
The five-year high for Cash from Operations was 2098000.0 in Q4 2024, with the low at 4028000.0 in Q2 2025.